1
|
Doi H, Matsui T, Dijkstra JM, Ogasawara A, Higashimoto Y, Imamura S, Ohye T, Takematsu H, Katsuda I, Akiyama H. Andrographolide, isolated from Andrographis paniculata, induces apoptosis in monocytic leukemia and multiple myeloma cells via augmentation of reactive oxygen species production. F1000Res 2022; 10:542. [PMID: 35528957 PMCID: PMC9069414 DOI: 10.12688/f1000research.53595.3] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 04/20/2022] [Indexed: 12/03/2022] Open
Abstract
Background: Andrographolide (Andro) is a diterpenoid component of the plant
Andrographis paniculata that is known for its anti-tumor activity against a variety of cancer cells. Methods: We studied the effects of Andro on the viability of the human leukemia monocytic cell line THP-1 and the human multiple myeloma cell line H929. Andro was compared with cytosine arabinoside (Ara-C) and vincristine (VCR), which are well-established therapeutics against hematopoietic tumors. The importance of reactive oxygen species (ROS) production for the toxicity of each agent was investigated by using an inhibitor of ROS production, N-acetyl-L-cysteine (NAC). Results: Andro reduced the viability of THP-1 and H929 in a concentration-dependent manner. H929 viability was highly susceptible to Andro, although only slightly susceptible to Ara-C. The agents Andro, Ara-C, and VCR each induced apoptosis, as shown by cellular shrinkage, DNA fragmentation, and increases in annexin V-binding, caspase-3/7 activity, ROS production, and mitochondrial membrane depolarization. Whereas Ara-C and VCR increased the percentages of cells in the G0/G1 and G2/M phases, respectively, Andro showed little or no detectable effect on cell cycle progression. The apoptotic activities of Andro were largely suppressed by NAC, an inhibitor of ROS production, whereas NAC hardly affected the apoptotic activities of Ara-C and VCR. Conclusions: Andro induces ROS-dependent apoptosis in monocytic leukemia THP-1 and multiple myeloma H929 cells, underlining its potential as a therapeutic agent for treating hematopoietic tumors. The high toxicity for H929 cells, by a mechanism that is different from that of Ara-C and VCR, is encouraging for further studies on the use of Andro against multiple myeloma.
Collapse
Affiliation(s)
- Hiroki Doi
- Field of Clinical Laboratory Sciences, Fujita Health University Graduate School of Health Sciences, Toyoake, 470-1192, Japan
| | - Taei Matsui
- Field of Clinical Laboratory Sciences, Fujita Health University Graduate School of Health Sciences, Toyoake, 470-1192, Japan
- Faculty of Medical Technology, Fujita Health University School of Medical Sciences, Toyoake, 470-1192, Japan
| | - Johannes M. Dijkstra
- Institute for Comprehensive Medical Science, Fujita Health University, Toyoake, 470-1192, Japan
| | - Atsushi Ogasawara
- Field of Clinical Laboratory Sciences, Fujita Health University Graduate School of Health Sciences, Toyoake, 470-1192, Japan
| | - Yuki Higashimoto
- Faculty of Medical Technology, Fujita Health University School of Medical Sciences, Toyoake, 470-1192, Japan
| | - Seiji Imamura
- Faculty of Medical Technology, Fujita Health University School of Medical Sciences, Toyoake, 470-1192, Japan
| | - Tamae Ohye
- Faculty of Medical Technology, Fujita Health University School of Medical Sciences, Toyoake, 470-1192, Japan
| | - Hiromu Takematsu
- Field of Clinical Laboratory Sciences, Fujita Health University Graduate School of Health Sciences, Toyoake, 470-1192, Japan
- Faculty of Medical Technology, Fujita Health University School of Medical Sciences, Toyoake, 470-1192, Japan
| | - Itsuro Katsuda
- Department of Hematology, Fujita Health University School of Medicine, Toyoake, 470-1192, Japan
| | - Hidehiko Akiyama
- Field of Clinical Laboratory Sciences, Fujita Health University Graduate School of Health Sciences, Toyoake, 470-1192, Japan
- Faculty of Medical Technology, Fujita Health University School of Medical Sciences, Toyoake, 470-1192, Japan
| |
Collapse
|
2
|
Duan Y, Dong X, Nie J, Li P, Lu F, Ma D, Ji C. Wee1 kinase inhibitor MK-1775 induces apoptosis of acute lymphoblastic leukemia cells and enhances the efficacy of doxorubicin involving downregulation of Notch pathway. Oncol Lett 2018; 16:5473-5481. [PMID: 30250620 DOI: 10.3892/ol.2018.9291] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2017] [Accepted: 01/18/2018] [Indexed: 11/06/2022] Open
Abstract
Acute lymphoblastic leukemia (ALL) is an aggressive hematologic malignancy affecting pediatric and adult populations. Although the outcomes of ALL in children have improved markedly in previous years, limited treatment strategies are available at present for adult patients with ALL. Wee1 is a crucial cell cycle checkpoint kinase of G2/M that regulates cell cycle progression and maintains chromatin integrity. MK-1775, a selective inhibitor of Wee1 has recently been identified to be able to induce apoptosis of tumor cells by abrogating G2/M checkpoint. The present study investigated the anti-leukemic activity of MK-1775 alone and in combination with doxorubicin (Adriamycin®; ADM) in various human ALL cell lines. MK-1775 treatment induced apoptosis of ALL cells, accompanied by unscheduled mitotic entry and downregulation of Notch pathway. The anti-leukemic activity of MK-1775 was in a concentration- and time-dependent manner. The data also indicated that it decreased the half-maximal inhibitory concentration (IC50) of ADM compared with the control group. The combination of MK-1775 and ADM induced an increased apoptotic rate compared with each agent alone. In addition, the human bone marrow stromal cell HS-5 cell line was detected to exhibit an increased IC50 value of MK-1775 treatment in contrast to ALL cell lines. It indicates that the hematopoietic supportive capability may remain intact during the treatment of MK-1775. Taken together, the Wee1 inhibitor MK-1775 may be an attractive agent in the treatment of patients with ALL.
Collapse
Affiliation(s)
- Yanchao Duan
- Department of Hematology, Qilu Hospital, Shandong University, Jinan, Shandong 250012, P.R. China.,Department of Hematology, Affiliated Hospital of Taishan Medical University, Taian, Shandong 271000, P.R. China
| | - Xin Dong
- Department of Hematology, Qilu Hospital, Shandong University, Jinan, Shandong 250012, P.R. China
| | - Jing Nie
- Department of Internal Medicine, The Central Hospital of Taian, Taian, Shandong 271000, P.R. China
| | - Peng Li
- Department of Hematology, Qilu Hospital, Shandong University, Jinan, Shandong 250012, P.R. China
| | - Fei Lu
- Department of Hematology, Qilu Hospital, Shandong University, Jinan, Shandong 250012, P.R. China
| | - Daoxin Ma
- Department of Hematology, Qilu Hospital, Shandong University, Jinan, Shandong 250012, P.R. China
| | - Chunyan Ji
- Department of Hematology, Qilu Hospital, Shandong University, Jinan, Shandong 250012, P.R. China
| |
Collapse
|
3
|
Ram R, Wolach O, Vidal L, Gafter-Gvili A, Shpilberg O, Raanani P. Adolescents and young adults with acute lymphoblastic leukemia have a better outcome when treated with pediatric-inspired regimens: systematic review and meta-analysis. Am J Hematol 2012; 87:472-8. [PMID: 22388572 DOI: 10.1002/ajh.23149] [Citation(s) in RCA: 103] [Impact Index Per Article: 8.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2011] [Revised: 01/07/2012] [Accepted: 01/30/2012] [Indexed: 11/10/2022]
Abstract
Survival of adults with acute lymphoblastic leukemia (ALL) is inferior to that of pediatric patients. Strategies to improve the outcome of adult population are warranted. This study aims to evaluate the efficacy and safety of pediatric-inspired regimens given to adolescents and young adults (AYA), usually defined as 16-39 years, with ALL. Systematic review and meta-analysis of comparative trials of AYA patients with ALL given induction chemotherapy with either pediatric-inspired regimens or conventional-adult chemotherapy was conducted. Relative risks (RR) with 95% confidence intervals (CIs) were estimated and pooled. Our search yielded 11 trials, including 2,489 patients. AYA patients given pediatric-inspired regimens had a statistically significant lower all cause mortality rate at 3 years (RR 0.58; 95% CI 0.51-0.67). Complete remission rate after induction chemotherapy and event free survival were superior in the pediatric-inspired regimens arm (RR 1.05; 95% CI 1.01-1.10 and RR 1.66; 95% CI 1.39-1.99, respectively). Relapse rate was also lower in patients given pediatric-inspired regimens (RR 0.51; 95% CI 0.39-0.66) with comparable nonrelapse mortality between the two groups (RR 0.53, 95% CI 0.19-1.48). Pediatric-inspired regimens are superior to conventional-adult chemotherapy in AYA ALL patients. Further randomized controlled studies to investigate this approach in adult ALL patients are warranted.
Collapse
Affiliation(s)
- Ron Ram
- Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Beilinson Hospital, Petah-Tiqva, Israel.
| | | | | | | | | | | |
Collapse
|
4
|
Tsurumi H, Hara T, Goto N, Kitagawa JI, Kanemura N, Yoshikawa T, Kasahara S, Goto H, Fukuno K, Yamada T, Sawada M, Shimizu M, Takahashi T, Takami T, Moriwaki H. A phase II study of rituximab combined with pirarubicin–cyclophosphamide, vincristine and prednisolone regimen as first-line therapy for patients with indolent B-cell lymphoma. Leuk Lymphoma 2011; 53:247-53. [DOI: 10.3109/10428194.2011.606383] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|